Copperwynd Financial LLC Has $711,000 Position in Danaher Co. (NYSE:DHR)

Copperwynd Financial LLC reduced its stake in Danaher Co. (NYSE:DHR) by 13.3% in the 4th quarter, Holdings Channel reports. The firm owned 3,097 shares of the conglomerate’s stock after selling 475 shares during the period. Copperwynd Financial LLC’s holdings in Danaher were worth $711,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Howard Capital Management Group LLC increased its position in Danaher by 4.1% in the 3rd quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock worth $342,000 after buying an additional 48 shares during the period. Harbour Investments Inc. increased its position in Danaher by 3.0% in the 3rd quarter. Harbour Investments Inc. now owns 1,531 shares of the conglomerate’s stock worth $426,000 after buying an additional 45 shares during the period. Empower Advisory Group LLC increased its position in Danaher by 2.1% in the 3rd quarter. Empower Advisory Group LLC now owns 2,558 shares of the conglomerate’s stock worth $711,000 after buying an additional 52 shares during the period. Kovack Advisors Inc. increased its position in Danaher by 3.4% in the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after buying an additional 41 shares during the period. Finally, CIBC Asset Management Inc increased its position in Danaher by 3.1% in the 3rd quarter. CIBC Asset Management Inc now owns 204,363 shares of the conglomerate’s stock worth $56,780,000 after buying an additional 6,086 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

Danaher stock opened at $211.09 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The firm has a market cap of $150.87 billion, a P/E ratio of 39.98, a P/E/G ratio of 2.66 and a beta of 0.82. The business’s fifty day moving average is $220.07 and its two-hundred day moving average is $240.82. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the company earned $2.09 EPS. Equities research analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a yield of 0.61%. This is a positive change from Danaher’s previous quarterly dividend of $0.27. Danaher’s payout ratio is currently 24.24%.

Insider Activity

In other news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 11.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on DHR. Robert W. Baird dropped their price target on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Citigroup lowered their price objective on Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Guggenheim assumed coverage on Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective on the stock. JPMorgan Chase & Co. lowered their price objective on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Finally, StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $277.76.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.